What is the latest CONCORDBIO stock price?
The latest stored price for CONCORDBIO is Rs 1,571.30 as of 2026-08-21.
gimli
CONCORDBIO stock AI analysis
CONCORDBIO Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
CONCORD BIOTECH LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available CONCORDBIO price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹1,571.30
1W return
+8.27%
1M return
+18.21%
3M return
+39.88%
6M return
+43.12%
1Y return
-10.22%
Market cap
₹16,438.34 cr
PE
60.17
PB
8.16
ROE
+14.27%
ROCE
+19.02%
RSI
74.89
Turnover
₹14.80 cr
Why it can matter in screens
- Momentum: CONCORDBIO is above 50DMA, above 200DMA; RSI is 74.89.
- Returns: 1D -0.34%, 1W +8.27%, 1M +18.21%, 3M +39.88%, 1Y -10.22%.
- Trend levels: 52W high ₹1,615.00, 52W low ₹1,022.20, off high -2.71%.
- Liquidity: latest turnover is ₹14.80 cr; volume vs 20D is +0.42%.
- Valuation/profitability: PE 60.17, PB 8.16, ROE +14.27%, ROCE +19.02%.
- Growth: 3Y sales CAGR +8.29%, 3Y profit CAGR +2.81%.
Quick Answers
Is CONCORDBIO above its 50DMA and 200DMA?
CONCORDBIO is above 50DMA, above 200DMA. The latest 50DMA is 1,357.97 and the latest 200DMA is 1,266.55.
What are CONCORDBIO PE, ROE and ROCE?
CONCORDBIO has PE 60.17, ROE +14.27%, and ROCE +19.02% in Gimli's latest available snapshot.
How has CONCORDBIO performed recently?
CONCORDBIO has returned +18.21% over 1 month, +39.88% over 3 months, and -10.22% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 257.49 cr | 96.48 cr | 57.70 cr | 8.46 |
| 2026-03-31 | 326.08 cr | 133.70 cr | 88.79 cr | 8.46 |
| 2025-12-31 | 277.77 cr | 104.98 cr | 63.64 cr | 6.08 |
| 2025-09-30 | 247.06 cr | 104.13 cr | 63.06 cr | 6.03 |
| 2025-06-30 | 203.99 cr | 76.57 cr | 44.06 cr | 4.21 |
| 2025-03-31 | 429.88 cr | 198.26 cr | 140.39 cr | 13.42 |
| 2024-12-31 | 244.22 cr | 114.51 cr | n/a | nan |
| 2024-09-30 | 310.18 cr | 143.75 cr | n/a | 9.15 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 1,054.89 cr | 419.39 cr | 260.91 cr | 25.17 |
| 2025-03-31 | 1,200.09 cr | 549.46 cr | 371.64 cr | 35.52 |
| 2024-03-31 | 998.06 cr | 468.71 cr | 308.10 cr | 29.45 |
| 2023-03-31 | 830.63 cr | 380.56 cr | 240.09 cr | 22.95 |
| 2022-03-31 | 736.35 cr | 293.05 cr | 178.57 cr | 16.72 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 2,234.73 cr | 12.19 cr | 2.32 cr | 2,015.14 cr |
| 2025-03-31 | 2,034.25 cr | 0.90 cr | 2.97 cr | 1,812.72 cr |
| 2024-03-31 | 1,700.71 cr | 15.14 cr | 9.74 cr | 1,526.65 cr |
| 2023-03-31 | 1,513.98 cr | 3.50 cr | 31.55 cr | 1,290.00 cr |
| 2022-03-31 | 1,312.80 cr | 0.67 cr | 62.49 cr | 1,103.22 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 266.88 cr | 171.73 cr | n/a |
| 2025-03-31 | 244.52 cr | 133.34 cr | n/a |
| 2024-03-31 | 265.47 cr | 179.78 cr | n/a |
| 2023-03-31 | 246.00 cr | 100.92 cr | n/a |
| 2022-03-31 | 207.47 cr | 51.97 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +44.08% | +7.52% | +9.36% | +4.40% | +39.03% | +0.00% |
| 2026-03-31 | +44.08% | +7.80% | +9.22% | +4.30% | +38.90% | +0.00% |
| 2025-12-31 | +44.08% | +7.58% | +9.58% | +4.44% | +38.76% | +0.00% |
| 2025-09-30 | +44.08% | +8.03% | +9.55% | +4.53% | +38.33% | +0.00% |
| 2025-06-30 | +44.08% | +9.11% | +8.87% | +4.68% | +37.95% | +0.00% |
| 2025-03-31 | +44.08% | +9.35% | +9.16% | +5.16% | +37.41% | +0.00% |
| 2024-12-31 | +44.08% | +8.33% | +9.66% | +4.86% | +37.93% | +0.00% |
| 2024-09-30 | +44.08% | +8.10% | +9.89% | +4.97% | +37.93% | +0.00% |
| 2024-06-30 | +44.08% | +7.11% | +10.40% | +5.26% | +38.41% | +0.00% |
| 2024-03-31 | +44.08% | +6.48% | +8.46% | +5.15% | +40.97% | +0.00% |
| 2023-12-31 | +44.08% | +7.00% | +8.46% | +5.65% | +40.46% | +0.00% |
| 2023-09-30 | +44.08% | +7.30% | +8.18% | +5.58% | +40.44% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze CONCORD BIOTECH with valuation, momentum and industry peers
- Compare CONCORDBIO with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare CONCORDBIO with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.